Evidence map›Paper›PMID 39966252›Full record

ArticleDrug delivery and translational research2025

Mixed dry reverse micelles: potential carriers for oral protein delivery via SEDDS.

Fabrizio Ricci, Sera Lindner, Simona Summonte, René Holm, Dajun Sun, Nathaniel Washburn, Cecilia Bohns Michalowski, Giustino Di Pretoro, Andreas Bernkop-Schnürch

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fabrizio RicciThiomatrix Forschungs-und Beratungs GmbH, Trientlgasse 65, Innsbruck, 6020, Austria.
Sera LindnerThiomatrix Forschungs-und Beratungs GmbH, Trientlgasse 65, Innsbruck, 6020, Austria.
Simona SummonteThiomatrix Forschungs-und Beratungs GmbH, Trientlgasse 65, Innsbruck, 6020, Austria.
René HolmDepartment of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, Odense, 5230, Denmark.
Dajun SunPharmaceutical Product Development & Supply, Johnson & Johnson Innovative Medicine, Turnhoutseweg 30, Beerse, B-2340, Belgium.
Nathaniel WashburnImmunology Discovery Johnson & Johnson Innovative Medicine, 301 Binney St, Cambridge, MA, 02141, USA.
Cecilia Bohns MichalowskiPharmaceutical Product Development & Supply, Johnson & Johnson Innovative Medicine, Turnhoutseweg 30, Beerse, B-2340, Belgium.
Giustino Di PretoroDrug Product Development & Delivery, Johnson & Johnson Innovative Medicine, 347 Phoenixville Pike, Malvern, PA, 19355, USA.
Andreas Bernkop-SchnürchThiomatrix Forschungs-und Beratungs GmbH, Trientlgasse 65, Innsbruck, 6020, Austria. a.bernkop@thiomatrix.com.ORCID 0000-0003-4187-8277

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to evaluate the potential of mixed dry reverse micelles (dRMs) to increase the lipophilicity of therapeutic proteins and allow their incorporation into self-emulsifying drug delivery systems (SEDDS). Horseradish peroxidase (HRP) was incorporated in mixed dRMs, forming HRP-dRMs, using soybean phosphatidylcholine (SPC) and sodium docusate (SD) as surfactants. HRP-dRMs were characterized with respect to their distribution coefficient and stability in simulated physiological fluids. Moreover, HRP-dRMs were loaded in SEDDS, which were characterized for their payload, stability, distribution coefficients between the lipophilic phase of SEDDS and release medium and their ability to protect the incorporated protein towards enzymatic degradation in aqueous media containing trypsin and chymotrypsin. The synergistic effect of two surfactants to form dRMs led to a payload of 3% (w/v) for the model protein in a lipophilic phase without the use of organic cosolvents. Moreover, the HRP-dRMs incorporation increased the LogD

Indexed as

Drug CarriersDrug Delivery SystemsMicellesAdministration, OralDioctyl Sulfosuccinic AcidEmulsionsHorseradish PeroxidasePhosphatidylcholinesSurface-Active AgentsDioctyl Sulfosuccinic AcidDrug CarriersEmulsionsHorseradish PeroxidaseMicellesPhosphatidylcholinesSurface-Active AgentsHydrophobic ion pairingOral drug deliverySelf-emulsifying drug delivery systemsTherapeutic proteins

Identifiers

PMID39966252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.